These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27107743)

  • 21. Loss of Pax5 promotes plasma cell differentiation.
    Nera KP; Kohonen P; Narvi E; Peippo A; Mustonen L; Terho P; Koskela K; Buerstedde JM; Lassila O
    Immunity; 2006 Mar; 24(3):283-93. PubMed ID: 16546097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5.
    Nutt SL; Heavey B; Rolink AG; Busslinger M
    Nature; 1999 Oct; 401(6753):556-62. PubMed ID: 10524622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of cyclin D1 contributes to malignancy by up-regulation of fibroblast growth factor receptor 1 via the pRB/E2F pathway.
    Tashiro E; Maruki H; Minato Y; Doki Y; Weinstein IB; Imoto M
    Cancer Res; 2003 Jan; 63(2):424-31. PubMed ID: 12543798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1.
    Kröger A; Stirnweiss A; Pulverer JE; Klages K; Grashoff M; Reimann J; Hauser H
    Cancer Res; 2007 Apr; 67(7):2972-81. PubMed ID: 17409403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.
    Cozma D; Yu D; Hodawadekar S; Azvolinsky A; Grande S; Tobias JW; Metzgar MH; Paterson J; Erikson J; Marafioti T; Monroe JG; Atchison ML; Thomas-Tikhonenko A
    J Clin Invest; 2007 Sep; 117(9):2602-10. PubMed ID: 17717600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.
    Duque-Afonso J; Feng J; Scherer F; Lin CH; Wong SH; Wang Z; Iwasaki M; Cleary ML
    J Clin Invest; 2015 Sep; 125(9):3667-80. PubMed ID: 26301816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Losing B cell identity.
    Carotta S; Nutt SL
    Bioessays; 2008 Mar; 30(3):203-7. PubMed ID: 18293359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.
    Leslie K; Lang C; Devgan G; Azare J; Berishaj M; Gerald W; Kim YB; Paz K; Darnell JE; Albanese C; Sakamaki T; Pestell R; Bromberg J
    Cancer Res; 2006 Mar; 66(5):2544-52. PubMed ID: 16510571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversion of B cell commitment upon loss of Pax5 expression.
    Mikkola I; Heavey B; Horcher M; Busslinger M
    Science; 2002 Jul; 297(5578):110-3. PubMed ID: 12098702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pax5--a critical inhibitor of plasma cell fate.
    Nera KP; Lassila O
    Scand J Immunol; 2006 Sep; 64(3):190-9. PubMed ID: 16918686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin D1-dependent regulation of B-myb activity in early stages of neuroblastoma differentiation.
    Cesi V; Tanno B; Vitali R; Mancini C; Giuffrida ML; Calabretta B; Raschellà G
    Cell Death Differ; 2002 Nov; 9(11):1232-9. PubMed ID: 12404122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.
    Wang Y; Thakur A; Sun Y; Wu J; Biliran H; Bollig A; Liao DJ
    Cancer Res; 2007 Apr; 67(8):3698-707. PubMed ID: 17440082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.
    Walter K; Cockerill PN; Barlow R; Clarke D; Hoogenkamp M; Follows GA; Richards SJ; Cullen MJ; Bonifer C; Tagoh H
    Oncogene; 2010 May; 29(20):2927-37. PubMed ID: 20208555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transient Notch signaling induces NK cell potential in Pax5-deficient pro-B cells.
    Carotta S; Brady J; Wu L; Nutt SL
    Eur J Immunol; 2006 Dec; 36(12):3294-304. PubMed ID: 17111353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pax5: a master regulator of B cell development and leukemogenesis.
    Medvedovic J; Ebert A; Tagoh H; Busslinger M
    Adv Immunol; 2011; 111():179-206. PubMed ID: 21970955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors.
    Rolink AG; Nutt SL; Melchers F; Busslinger M
    Nature; 1999 Oct; 401(6753):603-6. PubMed ID: 10524629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential regulation of sense and antisense promoter activity at the Csf1R locus in B cells by the transcription factor PAX5.
    Ingram RM; Valeaux S; Wilson N; Bouhlel MA; Clarke D; Krüger I; Kulu D; Suske G; Philipsen S; Tagoh H; Bonifer C
    Exp Hematol; 2011 Jul; 39(7):730-40.e1-2. PubMed ID: 21549805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
    Hu J; Colburn NH
    Mol Cancer Res; 2005 Feb; 3(2):100-9. PubMed ID: 15755876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ectopic expression of cyclin D1 impairs the proliferation and enhances the apoptosis of a murine lymphoid cell line.
    Duquesne F; Florent M; Roué G; Troussard X; Sola B
    Cell Death Differ; 2001 Jan; 8(1):51-62. PubMed ID: 11313703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors.
    Cobaleda C; Jochum W; Busslinger M
    Nature; 2007 Sep; 449(7161):473-7. PubMed ID: 17851532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.